Literature DB >> 29105625

Curative effect of Jin'gangteng capsule combined with Kangfuxiaoyan suppository in the treatment of chronic pelvic inflammatory disease.

Shanshan Gao1, Qing Zhang1.   

Abstract

This paper aims to analyze the curative effect of Jin'gangteng capsule combined with Kangfuxiaoyan suppository in the treatment of chronic pelvic inflammatory disease. 97 patients with chronic pelvic inflammatory disease admitted to our hospital from June 2015 to June 2016 were selected and randomly divided into observation group and control group. Patients in control group were treated with Kangfuxiaoyan suppository and patients in the observation group were treated with Jin'gangteng capsule combined with kangfuxiaoyan suppository treatment. The curative effect between the two groups was compared. The scores of symptoms and signs in the observation group after treatment were lower than those in the control group. The total effective rate of the observation group was higher than that of the control group, and there was significant difference between the two groups, P<0.05. Jin'gangteng capsule combined with Kangfuxiaoyan suppository in the treatment of chronic pelvic inflammatory disease can improve the treatment efficiency and promote the rapid and effective relief of clinical symptoms and signs.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29105625

Source DB:  PubMed          Journal:  Pak J Pharm Sci        ISSN: 1011-601X            Impact factor:   0.684


  2 in total

1.  Effect and Safety of Kangfuyan Capsules () for Relieving Chronic Pelvic Pain: A Multicenter, Randomized, Controlled, Double-Blind, Parallel-Group Clinical Trial.

Authors:  Zhao-Hui Liu; Zhe Jin; Hong Zhao; Yao Lu; Hui Zhen; Ting Zou
Journal:  Chin J Integr Med       Date:  2021-08-25       Impact factor: 1.978

2.  Kangfuxiaoyanshuan alleviates uterine inflammation and adhesion via inhibiting NF-κB p65 and TGF-β/MMP-2 signaling pathway in pelvic inflammatory disease rats.

Authors:  Linyuan Fan; Zhaohui Liu; Zhan Zhang; Ting Li; Xiaonan Zong; Huihui Bai
Journal:  Front Pharmacol       Date:  2022-07-18       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.